miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma
- 29 November 2016
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 40 (1) , 77-88
Abstract
Purpose Highly aggressive adult soft tissue sarcomas (STS), i.e., leiomyosarcomas (LMS) and undifferentiated pleomorphic sarcomas (UPS), present complex genomic anomalies and overall 5-year survival rates of 20 to 40%. Here, we aimed to identify new biomarkers that may be employed to improve the treatment of non-translocation STS patients. We validated 12 miRNAs implicated in tumor development using primary STS samples and selected miR-152 for further analysis in STS-derived cell lines. Methods 59 primary STS samples (27 LMS and 32 UPS) and 10 matched normal control tissues were included in the study, as well as 3 STS-derived cell lines (HT1080, SW872 and SKLMS1) and a normal control mesenchymal cell line (hMSC). miRNA expression analyses were performed using a TaqMan microRNA Array platform and qRT-PCR (miR-152), respectively. The expression levels of the putative miR-152 targets MET and KIT were assessed using qRT-PCR and immunohistochemistry on tissue microarrays, respectively. In addition, various functional analyses were performed before and after miR-152 transfection into SKLMS1 cells. Results We found that 12 pre-selected miRNAs were down-regulated in primary STS tumor samples compared to its normal control samples. A statistically significant miR-152 down-regulation was found to be accompanied by high MET and KIT mRNA levels in both the primary samples and the STS-derived cell lines tested. miR-152 transfection in SKLMS1 cells led to a reduction in KIT and MET mRNA and protein levels which, in turn, was associated with a transient down-regulation of the PI3K/AKT pathway, a transient decrease in cell growth, and a transient increase in both apoptotic and S-phase cells. Conclusions Our data indicate that over-expression of MET and KIT in primary STS samples and its derived cell lines is associated with miR-152 down-regulation. This shift may play a role in STS development and, thus, may be used to identify patients at risk. The effect of MET down-regulation on downstream signaling pathways, such as the PI3K/AKT pathway, may provide a basis for the future design of novel STS treatment strategies.Keywords
Funding Information
- FIRC Triennal fellowship “Mario e Valeria Rindi (13748)
- 5‰ donation (Italy)
This publication has 45 references indexed in Scilit:
- Causes and Consequences of MicroRNA DysregulationThe Cancer Journal, 2012
- Integrated analysis of mRNA and microRNA expression in mature neurons, neural progenitor cells and neuroblastoma cellsGene, 2012
- The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray studyHistopathology, 2011
- MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferationMolecular Cancer, 2011
- A Differentiation-Based MicroRNA Signature Identifies Leiomyosarcoma as a Mesenchymal Stem Cell-Related MalignancyThe American Journal of Pathology, 2010
- Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomasCancer Science, 2009
- Benign Metastasizing Leiomyoma of the LungDiagnostic Molecular Pathology, 2008
- Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCRBiological Procedures Online, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Classification of pleomorphic sarcomas: where are we now?Histopathology, 2005